← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Applied Genetic Technologies Corporation
Alachua, FL
$3,323,453
Total funding
6
Grants
Funding over time
peak $943.1K · FY2010–15$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
Funding mix
By agency
FDA$2,134,236 · 2
NIH$1,189,217 · 4
By mechanism
R01$2,134,236 · 2
R42$657,699 · 1
R43$531,518 · 3
Investigators at Applied Genetic Technologies Corporation
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$400,000
R01 · FY2010 · FD
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$400,000
R01 · FY2011 · FD
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$400,000
R01 · FY2010 · FD
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$385,045
R01 · FY2011 · FD
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model$290,016
R42 · FY2014 · EY
TREATMENT OF ANEMIA USING AAV VECTORS$256,725
R43 · FY2001 · HL
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$252,411
R01 · FY2012 · FD
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model$213,638
R42 · FY2015 · EY
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Safety and Efficacy in a Dog Model$154,045
R42 · FY2013 · EY
rAAV5-hCNGB3 Gene Therapy for Achromatopsia: Efficacy in a Dog Model$143,082
R43 · FY2010 · EY
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$139,545
R01 · FY2012 · FD
Molecular Breeding of Gene Therapy Vectors$131,711
R43 · FY2003 · HL
Phase 2 Study of rAAV1-CB-hAAT for Treatment of Alpha-1 Antitrypsin Deficiency$98,066
R01 · FY2013 · FD
Phase 1/2 Trial of rAAV2-CB-hRPE65 (BB-IND 13848, 11 Sep 2009) for Leber Congenit$59,169
R01 · FY2013 · FD